Barclays
RPRX

Barclays’s Repros Therapeutics Inc. RPRX Stock Holding History

Barclays’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-500
Closed -$1K – 7311
2016
Q4 		$1K Sell
500
-100
-17% -$174 ﹤0.01% 6569
2016
Q3 		$1K Sell
600
-3,900
-87% -$7.71K ﹤0.01% 6575
2016
Q2 		$7K Buy
+4,500
New +$8.63K ﹤0.01% 5686
2016
Q1 		– Sell
-13,900
Closed -$14K – 6927
2015
Q4 		$14K Buy
13,900
+4,600
+49% +$14.8K ﹤0.01% 5324
2015
Q3 		$65K Sell
9,300
-6,200
-40% -$47.4K ﹤0.01% 4877
2015
Q2 		$109K Sell
15,500
-400
-3% -$3.12K ﹤0.01% 4607
2015
Q1 		$127K Sell
15,900
-35,200
-69% -$315K ﹤0.01% 4690
2014
Q4 		$460K Sell
51,100
-157,400
-75% -$1.34M ﹤0.01% 3934
2014
Q3 		$1.88M Buy
208,500
+173,600
+497% +$2.57M ﹤0.01% 2722
2014
Q2 		$593K Buy
34,900
+10,300
+42% +$168K ﹤0.01% 3817
2014
Q1 		$418K Buy
24,600
+16,200
+193% +$313K ﹤0.01% 4108
2013
Q4 		$151K Sell
8,400
-283,000
-97% -$5.34M ﹤0.01% 5283
2013
Q3 		$7.58M Sell
291,400
-348,700
-54% -$7.47M 0.01% 1367
2013
Q2 		$11.8M Buy
+640,100
New +$11.3M 0.01% 967

Barclays's RPRX Position: Q1 2018 in Review

Barclays sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 124 shares.

Barclays first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $7.87M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Barclays reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Barclays sold 124 Repros Therapeutics Inc. shares in Q1 2018.
  • Barclays first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
  • Barclays's Repros Therapeutics Inc. position peaked at $7.87M in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.